Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART

Franco Pandolfi, Marina Pierdominici, Marco Marziali, Maria Livia Bernardi, Guido Antonelli, Vincenzo Galati, Gianpiero D'Offizi, Fernando Aiuti

Research output: Contribution to journalArticle

Abstract

During HIV disease an increased in vitro apoptosis of peripheral blood mononuclear cells has been demonstrated. This can be reversed in vitro by interleukin (IL)-2. Recent trials with highly active antiretroviral therapy (HAART) and IL-2 in HIV-1-infected patients showed promising immunological and clinical results. Here we investigated the effects of subcutaneous low- dose IL-2 administration in combination with HAART on in vitro apoptosis and the relationship between apoptosis, CD4+ counts, and HIV replication. Twenty-two asymptomatic HIV patients were randomized for HAART (arm I) and HAART plus IL-2 (arm II). Spontaneous apoptosis was decreased in both arms after 28 weeks of therapy but the reduction was highly significant only in arm II (P = 0.05 vs P = 0.001). As the percentage of apoptosis decreased, there was a significantly higher increase of both CD4+ and CD4+ naive T cells in arm II vs arm I. HIV plasma viremia was reduced in all patients after therapy. Our data suggest that intermittent therapy with low-dose subcutaneous IL-2 in addition to HAART induces a positive immunomodulation in asymptomatic HIV-infected patients. (C) 2000 Academic Press.

Original languageEnglish
Pages (from-to)153-159
Number of pages7
JournalClinical Immunology
Volume94
Issue number3
DOIs
Publication statusPublished - Mar 2000

Fingerprint

Highly Active Antiretroviral Therapy
Interleukin-2
HIV-1
HIV
Lymphocytes
Apoptosis
Immunomodulation
Viremia
CD4 Lymphocyte Count
Blood Cells
Therapeutics
T-Lymphocytes
In Vitro Techniques

Keywords

  • Apoptosis
  • CD4 T cells
  • HIV viremia
  • Interleukin-2

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

Pandolfi, F., Pierdominici, M., Marziali, M., Livia Bernardi, M., Antonelli, G., Galati, V., ... Aiuti, F. (2000). Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. Clinical Immunology, 94(3), 153-159. https://doi.org/10.1006/clim.2000.4837

Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. / Pandolfi, Franco; Pierdominici, Marina; Marziali, Marco; Livia Bernardi, Maria; Antonelli, Guido; Galati, Vincenzo; D'Offizi, Gianpiero; Aiuti, Fernando.

In: Clinical Immunology, Vol. 94, No. 3, 03.2000, p. 153-159.

Research output: Contribution to journalArticle

Pandolfi, F, Pierdominici, M, Marziali, M, Livia Bernardi, M, Antonelli, G, Galati, V, D'Offizi, G & Aiuti, F 2000, 'Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART', Clinical Immunology, vol. 94, no. 3, pp. 153-159. https://doi.org/10.1006/clim.2000.4837
Pandolfi, Franco ; Pierdominici, Marina ; Marziali, Marco ; Livia Bernardi, Maria ; Antonelli, Guido ; Galati, Vincenzo ; D'Offizi, Gianpiero ; Aiuti, Fernando. / Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART. In: Clinical Immunology. 2000 ; Vol. 94, No. 3. pp. 153-159.
@article{efa4df8ba99c47b7961a2510d736a4fc,
title = "Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART",
abstract = "During HIV disease an increased in vitro apoptosis of peripheral blood mononuclear cells has been demonstrated. This can be reversed in vitro by interleukin (IL)-2. Recent trials with highly active antiretroviral therapy (HAART) and IL-2 in HIV-1-infected patients showed promising immunological and clinical results. Here we investigated the effects of subcutaneous low- dose IL-2 administration in combination with HAART on in vitro apoptosis and the relationship between apoptosis, CD4+ counts, and HIV replication. Twenty-two asymptomatic HIV patients were randomized for HAART (arm I) and HAART plus IL-2 (arm II). Spontaneous apoptosis was decreased in both arms after 28 weeks of therapy but the reduction was highly significant only in arm II (P = 0.05 vs P = 0.001). As the percentage of apoptosis decreased, there was a significantly higher increase of both CD4+ and CD4+ naive T cells in arm II vs arm I. HIV plasma viremia was reduced in all patients after therapy. Our data suggest that intermittent therapy with low-dose subcutaneous IL-2 in addition to HAART induces a positive immunomodulation in asymptomatic HIV-infected patients. (C) 2000 Academic Press.",
keywords = "Apoptosis, CD4 T cells, HIV viremia, Interleukin-2",
author = "Franco Pandolfi and Marina Pierdominici and Marco Marziali and {Livia Bernardi}, Maria and Guido Antonelli and Vincenzo Galati and Gianpiero D'Offizi and Fernando Aiuti",
year = "2000",
month = "3",
doi = "10.1006/clim.2000.4837",
language = "English",
volume = "94",
pages = "153--159",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART

AU - Pandolfi, Franco

AU - Pierdominici, Marina

AU - Marziali, Marco

AU - Livia Bernardi, Maria

AU - Antonelli, Guido

AU - Galati, Vincenzo

AU - D'Offizi, Gianpiero

AU - Aiuti, Fernando

PY - 2000/3

Y1 - 2000/3

N2 - During HIV disease an increased in vitro apoptosis of peripheral blood mononuclear cells has been demonstrated. This can be reversed in vitro by interleukin (IL)-2. Recent trials with highly active antiretroviral therapy (HAART) and IL-2 in HIV-1-infected patients showed promising immunological and clinical results. Here we investigated the effects of subcutaneous low- dose IL-2 administration in combination with HAART on in vitro apoptosis and the relationship between apoptosis, CD4+ counts, and HIV replication. Twenty-two asymptomatic HIV patients were randomized for HAART (arm I) and HAART plus IL-2 (arm II). Spontaneous apoptosis was decreased in both arms after 28 weeks of therapy but the reduction was highly significant only in arm II (P = 0.05 vs P = 0.001). As the percentage of apoptosis decreased, there was a significantly higher increase of both CD4+ and CD4+ naive T cells in arm II vs arm I. HIV plasma viremia was reduced in all patients after therapy. Our data suggest that intermittent therapy with low-dose subcutaneous IL-2 in addition to HAART induces a positive immunomodulation in asymptomatic HIV-infected patients. (C) 2000 Academic Press.

AB - During HIV disease an increased in vitro apoptosis of peripheral blood mononuclear cells has been demonstrated. This can be reversed in vitro by interleukin (IL)-2. Recent trials with highly active antiretroviral therapy (HAART) and IL-2 in HIV-1-infected patients showed promising immunological and clinical results. Here we investigated the effects of subcutaneous low- dose IL-2 administration in combination with HAART on in vitro apoptosis and the relationship between apoptosis, CD4+ counts, and HIV replication. Twenty-two asymptomatic HIV patients were randomized for HAART (arm I) and HAART plus IL-2 (arm II). Spontaneous apoptosis was decreased in both arms after 28 weeks of therapy but the reduction was highly significant only in arm II (P = 0.05 vs P = 0.001). As the percentage of apoptosis decreased, there was a significantly higher increase of both CD4+ and CD4+ naive T cells in arm II vs arm I. HIV plasma viremia was reduced in all patients after therapy. Our data suggest that intermittent therapy with low-dose subcutaneous IL-2 in addition to HAART induces a positive immunomodulation in asymptomatic HIV-infected patients. (C) 2000 Academic Press.

KW - Apoptosis

KW - CD4 T cells

KW - HIV viremia

KW - Interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=0034105525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034105525&partnerID=8YFLogxK

U2 - 10.1006/clim.2000.4837

DO - 10.1006/clim.2000.4837

M3 - Article

C2 - 10692234

AN - SCOPUS:0034105525

VL - 94

SP - 153

EP - 159

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -